XTX Topco Ltd Buys Shares of 39,999 Hims & Hers Health, Inc. (NYSE:HIMS)

XTX Topco Ltd bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 39,999 shares of the company’s stock, valued at approximately $808,000.

A number of other hedge funds have also recently added to or reduced their stakes in HIMS. Victory Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 23.0% during the fourth quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock worth $163,000 after purchasing an additional 3,429 shares during the period. Diversify Advisory Services LLC acquired a new position in shares of Hims & Hers Health during the first quarter worth $701,000. Sei Investments Co. lifted its holdings in shares of Hims & Hers Health by 206.9% during the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares during the period. Quantbot Technologies LP lifted its holdings in shares of Hims & Hers Health by 3,444.9% during the first quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after purchasing an additional 208,621 shares during the period. Finally, Quadrature Capital Ltd lifted its holdings in shares of Hims & Hers Health by 494.2% during the first quarter. Quadrature Capital Ltd now owns 201,043 shares of the company’s stock worth $3,108,000 after purchasing an additional 167,211 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total transaction of $38,593.50. Following the completion of the sale, the insider now directly owns 176,952 shares of the company’s stock, valued at $2,919,708. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,546 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $22.21, for a total value of $256,436.66. Following the completion of the sale, the chief financial officer now directly owns 177,449 shares of the company’s stock, valued at approximately $3,941,142.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50. Following the completion of the sale, the insider now directly owns 176,952 shares of the company’s stock, valued at $2,919,708. The disclosure for this sale can be found here. Insiders sold a total of 684,601 shares of company stock valued at $11,967,928 over the last three months. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Down 3.7 %

HIMS opened at $16.30 on Monday. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74. The company has a market cap of $3.50 billion, a P/E ratio of -1,630.00 and a beta of 1.05. The company has a fifty day moving average price of $17.35 and a two-hundred day moving average price of $17.07.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm’s revenue for the quarter was up 51.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.03) earnings per share. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. Jefferies Financial Group boosted their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. TD Cowen boosted their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Finally, Truist Financial boosted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.86.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.